Table 3 Open in new tab Comparison of...

	Atrial fibrillation	Left heart disease	Pulmonary hypertension	Tetralogy of Fallot
Age (years)	71 (69–80)	78 (72–83)	64 (60–69)	68 (52–77)	52 (43–66)	60 (47–74)	21 (19–25)	20 (14–23)
Women, n (%)	20 (71)	41 (59)	37 (50)	30 (45)	56 (74)	80 (80)	15 (47)	20 (47)
TA area at ED (cm²/m²)	4.9 (4.5–5.7)	7.3 (6.1–8.8)^*	4.9 (4.5–5.6)	7.7 (6.5–9.0)^*	4.8 (4.4–5.3)	7.5 (6.0–8.9)^*	5.3 (4.7–5.7)	6.1 (5.3–7.3)^*
Tenting volume (mL)	2.6 (2.1–2.9)	3.6 (2.5–5.1)^*	2.6 (2.2–3.3)	4.6 (3.4–7.3)^*	2.6 (2.2–3.0)	4.4 (3.0–6.3)^*	2.7 (1.9–3.6)	2.3 (1.7–3.5)
RAVmax (mL/m²)	27 (22–31)	66 (46–79)^*	28 (23–35)	46 (38–67)^*	28 (24–34)	50 (35–62)^*	24 (19–30)	31 (25–41)
RVEDV (mL/m²)	63 (53–79)	67 (59–82)	62 (54–77)	102 (81–161)^*	61 (52–75)	115 (89–146)^*	130 (116–159)	71 (55–76)^*
RVEF (%)	59 (57–63)	51 (46–53)^*	58 (53–62)	45 (35–51)^*	59 (56–62)	41 (35–46)^*	56 (52–59)	44 (39–47)^*

Atrial fibrillation

Left heart disease

Pulmonary hypertension

Tetralogy of Fallot

Parameter

Controls (n = 28)

Patients (n = 70)

Controls (n = 74)

Patients (n = 66)

Controls (n = 76)

Patients (n = 101)

Controls (n = 32)

Patients (n = 43)

Age (years)

71 (69–80)

78 (72–83)

64 (60–69)

68 (52–77)

52 (43–66)

60 (47–74)

21 (19–25)

20 (14–23)

Women, n (%)

20 (71)

41 (59)

37 (50)

30 (45)

56 (74)

80 (80)

15 (47)

20 (47)

TA area at ED (cm²/m²)

4.9 (4.5–5.7)

7.3 (6.1–8.8)^*

4.9 (4.5–5.6)

7.7 (6.5–9.0)^*

4.8 (4.4–5.3)

7.5 (6.0–8.9)^*

5.3 (4.7–5.7)

6.1 (5.3–7.3)^*

Tenting volume (mL)

2.6 (2.1–2.9)

3.6 (2.5–5.1)^*

2.6 (2.2–3.3)

4.6 (3.4–7.3)^*

2.6 (2.2–3.0)

4.4 (3.0–6.3)^*

2.7 (1.9–3.6)

2.3 (1.7–3.5)

RAVmax (mL/m²)

27 (22–31)

66 (46–79)^*

28 (23–35)

46 (38–67)^*

28 (24–34)

50 (35–62)^*

24 (19–30)

31 (25–41)

RVEDV (mL/m²)

63 (53–79)

67 (59–82)

62 (54–77)

102 (81–161)^*

61 (52–75)

115 (89–146)^*

130 (116–159)

71 (55–76)^*

RVEF (%)

59 (57–63)

51 (46–53)^*

58 (53–62)

45 (35–51)^*

59 (56–62)

41 (35–46)^*

56 (52–59)

44 (39–47)^*

	Atrial fibrillation	Left heart disease	Pulmonary hypertension	Tetralogy of Fallot
Age (years)	71 (69–80)	78 (72–83)	64 (60–69)	68 (52–77)	52 (43–66)	60 (47–74)	21 (19–25)	20 (14–23)
Women, n (%)	20 (71)	41 (59)	37 (50)	30 (45)	56 (74)	80 (80)	15 (47)	20 (47)
TA area at ED (cm²/m²)	4.9 (4.5–5.7)	7.3 (6.1–8.8)^*	4.9 (4.5–5.6)	7.7 (6.5–9.0)^*	4.8 (4.4–5.3)	7.5 (6.0–8.9)^*	5.3 (4.7–5.7)	6.1 (5.3–7.3)^*
Tenting volume (mL)	2.6 (2.1–2.9)	3.6 (2.5–5.1)^*	2.6 (2.2–3.3)	4.6 (3.4–7.3)^*	2.6 (2.2–3.0)	4.4 (3.0–6.3)^*	2.7 (1.9–3.6)	2.3 (1.7–3.5)
RAVmax (mL/m²)	27 (22–31)	66 (46–79)^*	28 (23–35)	46 (38–67)^*	28 (24–34)	50 (35–62)^*	24 (19–30)	31 (25–41)
RVEDV (mL/m²)	63 (53–79)	67 (59–82)	62 (54–77)	102 (81–161)^*	61 (52–75)	115 (89–146)^*	130 (116–159)	71 (55–76)^*
RVEF (%)	59 (57–63)	51 (46–53)^*	58 (53–62)	45 (35–51)^*	59 (56–62)	41 (35–46)^*	56 (52–59)	44 (39–47)^*

Table 3

Open in new tab

Comparison of FTR groups with age- and gender-matched controls

	Atrial fibrillation		Left heart disease		Pulmonary hypertension		Tetralogy of Fallot
Parameter	Controls (n = 28)	Patients (n = 70)	Controls (n = 74)	Patients (n = 66)	Controls (n = 76)	Patients (n = 101)	Controls (n = 32)	Patients (n = 43)
Age (years)	71 (69–80)	78 (72–83)	64 (60–69)	68 (52–77)	52 (43–66)	60 (47–74)	21 (19–25)	20 (14–23)
Women, n (%)	20 (71)	41 (59)	37 (50)	30 (45)	56 (74)	80 (80)	15 (47)	20 (47)
TA area at ED (cm²/m²)	4.9 (4.5–5.7)	7.3 (6.1–8.8)^*	4.9 (4.5–5.6)	7.7 (6.5–9.0)^*	4.8 (4.4–5.3)	7.5 (6.0–8.9)^*	5.3 (4.7–5.7)	6.1 (5.3–7.3)^*
Tenting volume (mL)	2.6 (2.1–2.9)	3.6 (2.5–5.1)^*	2.6 (2.2–3.3)	4.6 (3.4–7.3)^*	2.6 (2.2–3.0)	4.4 (3.0–6.3)^*	2.7 (1.9–3.6)	2.3 (1.7–3.5)
RAVmax (mL/m²)	27 (22–31)	66 (46–79)^*	28 (23–35)	46 (38–67)^*	28 (24–34)	50 (35–62)^*	24 (19–30)	31 (25–41)
RVEDV (mL/m²)	63 (53–79)	67 (59–82)	62 (54–77)	102 (81–161)^*	61 (52–75)	115 (89–146)^*	130 (116–159)	71 (55–76)^*
RVEF (%)	59 (57–63)	51 (46–53)^*	58 (53–62)	45 (35–51)^*	59 (56–62)	41 (35–46)^*	56 (52–59)	44 (39–47)^*

	Atrial fibrillation		Left heart disease		Pulmonary hypertension		Tetralogy of Fallot
Parameter	Controls (n = 28)	Patients (n = 70)	Controls (n = 74)	Patients (n = 66)	Controls (n = 76)	Patients (n = 101)	Controls (n = 32)	Patients (n = 43)
Age (years)	71 (69–80)	78 (72–83)	64 (60–69)	68 (52–77)	52 (43–66)	60 (47–74)	21 (19–25)	20 (14–23)
Women, n (%)	20 (71)	41 (59)	37 (50)	30 (45)	56 (74)	80 (80)	15 (47)	20 (47)
TA area at ED (cm²/m²)	4.9 (4.5–5.7)	7.3 (6.1–8.8)^*	4.9 (4.5–5.6)	7.7 (6.5–9.0)^*	4.8 (4.4–5.3)	7.5 (6.0–8.9)^*	5.3 (4.7–5.7)	6.1 (5.3–7.3)^*
Tenting volume (mL)	2.6 (2.1–2.9)	3.6 (2.5–5.1)^*	2.6 (2.2–3.3)	4.6 (3.4–7.3)^*	2.6 (2.2–3.0)	4.4 (3.0–6.3)^*	2.7 (1.9–3.6)	2.3 (1.7–3.5)
RAVmax (mL/m²)	27 (22–31)	66 (46–79)^*	28 (23–35)	46 (38–67)^*	28 (24–34)	50 (35–62)^*	24 (19–30)	31 (25–41)
RVEDV (mL/m²)	63 (53–79)	67 (59–82)	62 (54–77)	102 (81–161)^*	61 (52–75)	115 (89–146)^*	130 (116–159)	71 (55–76)^*
RVEF (%)	59 (57–63)	51 (46–53)^*	58 (53–62)	45 (35–51)^*	59 (56–62)	41 (35–46)^*	56 (52–59)	44 (39–47)^*

Values are median (I–III quartiles).

ED, end-diastole; FTR, functional tricuspid regurgitation; RAVmax, indexed right atrial volume; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; TA, tricuspid annulus.

P < 0.05.

This Feature Is Available To Subscribers Only